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Abstract
Background:  Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against
hepatocellular carcinoma in vitro. In a phase II trial, we investigated safety and efficacy including selection criteria
for best response in advanced or metastasised hepatocellular carcinoma.
Methods: 44 patients (84 % male, median age 69 years) not suitable or refractory to conventional therapy
received thymostimulin 75 mg subcutaneously five times per week for a median of 8.2 months until progression
or complete response. 3/44 patients were secondarily accessible to local ablation or chemoembolisation. Primary
endpoint was overall survival, secondary endpoint tumor response or progression-free survival. A multivariate
Cox's regression model was used to identify variables affecting survival.
Results: Median survival was 11.5 months (95% CI 7.9–15.0) with a 1-, 2- and 3-year survival of 50%, 23% and
9%. In the univariate analysis, a low Child-Pugh-score (p = 0.01), a low score in the Okuda- and CLIP-classification
(p < 0.001) or a low AFP-level (p < 0.001) were associated with better survival, but not therapy modalities other
than thymostimulin (p = 0.1) or signs of an invasive HCC phenotype such as vascular invasion (p = 0.3) and
metastases (p = 0.1). The only variables independently related to survival in the Cox's regression model were
Okuda stage and presence of liver cirrhosis (p < 0.01) as well as response to thymostimulin (p < 0.05). Of 39/44
patients evaluable for response, two obtained complete responses (one after concomitant radiofrequency
ablation), five partial responses (objective response 18%), twenty-four stable disease (tumor control rate 79%)
and eight progressed. Median progression-free survival was 6.4 months (95% CI 0.8–12). Grade 1 local reactions
following injection were the only side effects.
Conclusion: Outcome in our study rather depended on liver function and intrahepatic tumor growth (presence
of liver cirrhosis and Okuda stage) in addition to response to thymostimulin, while an invasive HCC phenotype
had no influence in the multivariate analysis. Thymostimulin could therefore be considered a safe and promising
candidate for palliative treatment in a selected target population with advanced hepatocellular carcinoma, in
particular as component of a multimodal therapy concept.
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Background
While the incidence of hepatocellular carcinoma (HCC) is
rising worldwide [1], only 25% of patients benefit from
curative treatment and transarterial chemoembolisation
(TACE) appears the only palliative therapy with proven
benefit for intermediate stages of the tumor [2-4]. For
patients with advanced or metastatic disease, no standard
treatment has been established resulting in a life expect-
ancy of less than 10% at 3 years. Systemic chemotherapy
in particular has been disappointing, not only because of
the chemoresistance of HCC, but because of major side-
effects poorly tolerated by patients with liver cirrhosis.
Immunomodulation is a promising experimental strategy
against HCC [5]. While interferon-based therapy has also
been poorly tolerated with little benefit in clinical trials,
thymostimulin showed an overall response rate of 24%
associated with a significant increase in life expectancy in
the only clinical phase II trial to date [6]. Moreover, virtu-
ally no side-effects were apparent. Isolated from calf thy-
mus, thymostimulin is a standardized low-molecular
protein fraction including thymosin-α1 and thymic
humoral factor [7,8]. It has been shown to induce the pro-
liferation and differentiation of T-lymphocytes and to
stimulate the release of interferons and interleukin-2 [9].
In vitro, thymostimulin activates a selective dose-depend-
ent cytotoxic reaction of Kupffer cells against HCC cell
lines [10]. However, the antineoplastic effect in vivo and
thus the patients likely profiting from therapy remain
unclear.
This phase II trial was designed to substantiate the safety
and efficacy of thymostimulin in the treatment of
advanced HCC and identify clinical criteria to select
patients benefiting from a randomized, controlled trial.
Methods
Eligibility
Patients with locally advanced or metastatic HCC not
amenable to or failing established treatment were
enrolled. Lesions were histologically proven or highly sus-
picious of HCC in two independent imaging techniques
with elevated α-fetoprotein levels (AFP) over 400 ng/ml.
Pretreatment of the HCC was allowed in case of tumor
progress with the respective therapy; however, no treat-
ment was to be given for at least 3 weeks prior to enroll-
ment. Patients were required to be between 18 and 80
years of age and have an ECOG performance status of ≤ 3.
Exclusion criteria were pregnancy/lactation, active second
malignancy, severe concomitant disease (e.g. NYHA III-
IV, serum creatinine level > 300 μmol/l) or severe decom-
pensated liver function (bilirubin > 5 mg/dl, INR ≥ 2.3).
None of the patients received anti-viral treatment with
interferon. Ethical approval was obtained from the local
ethical review board before study initiation and written
informed consent from each patient before entering the
study. The study was conducted in accordance with the
ethical principles stated in the Declaration of Helsinki and
the guidelines on good clinical practice.
Study design
The study was designed as a prospective, uncontrolled and
single-centre phase II trial, investigating effect and safety
of thymostimulin in patients with advanced HCC. In case
of tumor regress, secondary treatment of the HCC with
loco-regional modalities was permitted. Primary end-
points of the study were overall survival as well as 1-, 2-
and 3-year survival, secondary endpoints tumor response
and progression-free survival according to standard WHO
criteria, as well as toxicity according to ECOG criteria
[11,12].
Treatment
Thymostimulin is a licensed immunomodulating drug
prepared from an extract of peptides from bovine thymus
glands (Thymophysin CytoChemia®  25/50). Following
removal of high-molecular cell components and proteins,
the low-molecular active thymus peptides are isolated and
standardized to a defined protein fraction. All patients
received thymostimulin 75 mg subcutaneously for 5 days
a week according to manufacturers specifications in addi-
tion to best supportive care as required. Treatment with
thymostimulin was continued until one of the following
criteria was met: disease progression, death of patient,
unacceptable toxicity, patient refusal or incompliance,
complete response for more than 5 months. Patients with
tumor regress were allowed non-systemic concomitant
treatment with radiofrequency thermal ablation (RFTA)
or transarterial chemoembolisation (TACE), if the tumor
was found to be accessible secondary to the study treat-
ment. In case of tumor progress, patients were allowed to
receive salvage therapy at the investigator's discretion.
Pretreatment and follow-up evaluation
Pre-treatment and follow-up evaluation included a com-
plete medical history, physical examination, blood count
and chemistry as well as performance status. Cause, risk
factors and extent of liver disease according to Child-Pugh
status as well as prior treatment modalities were recorded
at baseline. Tumors were assessed by abdominal ultra-
sound, chest X-ray and either dynamic computerized tom-
ography (CT) or magnetic resonance imaging (MRI);
Okuda- and CLIP-classifications were used for staging.
Follow-up investigations were conducted at 6 and 12
weeks, and every three months thereafter until the end of
the study. They also included survival data and documen-
tation of concomitant therapies and toxicity of the medi-
cation. Tumor response was measured using abdominal
ultrasound and CT or MRI scanning and evaluated accord-BMC Cancer 2008, 8:72 http://www.biomedcentral.com/1471-2407/8/72
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ing to WHO criteria by an experienced radiologist (C.
Behrmann).
Statistical methods
All analyses were by intention to treat. Comparisons of
continuous variables were done by the Wilcoxon rank-
sum method and for categorical variables by the Fisher's
exact test. Survival time and progression-free survival were
calculated from the start of therapy to the date of death or
date of progression/death without progression, respec-
tively. Surviving patients with a complete response were
censored at the time of analysis. Survival curves were
established with the Kaplan-Meier method, a stepwise for-
ward Cox's regression analysis of survival was used to
assess baseline predictors and the treatment effect simul-
taneously. The following variables were chosen for the
univariate analysis: age, sex, weight, the presence of liver
cirrhosis and Child classification, Okuda stage and CLIP
score, AFP-level, multifocal tumor manifestation, ascites,
vascular invasion, extrahepatic metastases, treatment with
thymostimulin and treatment with other therapy modali-
ties before or after study entry. Significant variables in the
univariate analysis were introduced into the multivariate
analysis. Calculations were done with the SPSS package
(version 12.0.1).
Results
Patient characteristics
A total of 48 Caucasian patients were enrolled from July
2000 until September 2002. Four of the patients withdrew
their consent before the first dose of thymostimulin was
administered and their data had to be censored. The final
study population consisted of 37 men and 7 women.
Detailed demographic data and tumor-related characteris-
tics are depicted in Table 1. Most patients had liver cirrho-
sis (84%) and 32% of participants suffered from deranged
liver function at study entry (Child-Pugh-Score ≥ 7).
Using the Okuda- and CLIP-classification, a majority of
tumors were staged as intermediate HCC (Okuda stage II:
64%; CLIP 1–3 points: 79%); however, 32% showed signs
of vascular invasion and 21% had extrahepatic metas-
tases. About half of the patients (55%) had been treated
prior to enrollment with surgical resection (R1 or R2
resection), RFTA (range 1–3 sessions), TACE (range 1–9
sessions) or systemic chemotherapy (mytomycin C,
tamoxifen, retinoic acid or somatostatin), but suffered
from tumor progression.
Treatment summary
At the time of analysis, all patients had stopped treatment
with thymostimulin (Table 2) and 42 (96%) out of 44
patients had died, either because of tumor progression (n
= 29/66%), hepatic failure (n = 10/23%) or causes unre-
lated to the HCC (n = 3/7%). The median follow-up was
11.8 months (range 0.4 to 56.8 months), the median
length of treatment 8.2 months (range 0.4 to 54.3
months). 19 patients (43%) were solely treated with thy-
mostimulin for the HCC with no other therapy modalities
before or after study entry. Three patients (7%) showed a
partial response to the study medication with tumors sec-
ondarily accessible to RFTA (1–2 sessions) or TACE (3 ses-
sions). Two out of 44 patients received salvage therapy
after tumor progression; one was treated with RFTA, the
other died during an attempted hepatic resection. All
patients were included in the intention-to-treat analysis of
survival; however, 5 patients died within 6 weeks of
enrollment before the first follow-up visit and their data
were censored for the assessment of the treatment
response.
Overall survival
The median survival for all patients started on thymostim-
ulin was 11.5 months (95% CI 7.9–15.0) with two
patients remaining alive at the time of analysis (Figure 1).
Table 1: Patient characteristics
Characteristics (n = 44)
Patients
Male/female, n (%) 37/7 (84/16)
Median age, years (range) 69 (41–80)
Median weight, kg (range) 74 (58–123)
Origin of liver disease, n (%)
Alcohol abuse 20 (46)
HBV/HCV 8 (18)
NASH 5 (11)
Cryptogenic 11 (25)
Tumor stage, n (%)
Liver cirrhosis 37 (84)
Child classification A/B/C 23/9/5 (52/21/11)
Okuda stage I/II/III 13/28/3 (29/64/7)
CLIP 0/1–3/4–6 2/35/7 (5/79/16)
α-FP (ng/ml), n (%)
< 400 29 (66)
400- 10000 8 (18)
> 10000 7 (16)
Tumor characteristics, n (%)
Ascites 13 (30)
Portal vein thrombosis 14 (32)
Multifocal tumor manifestation 38 (86)
Extrahepatic metastases 9 (21)
Previous treatment, n (%)
(combination possible)
Surgery 4 (9)
Radiofrequency ablation 5 (11)
Transarterial chemoembolisation 17 (39)
Systemic chemotherapy 4 (9)BMC Cancer 2008, 8:72 http://www.biomedcentral.com/1471-2407/8/72
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The probabilities of survival at 1, 2 and 3 years were 50%,
23% and 9%, respectively. Patients solely treated with thy-
mostimulin for the HCC had a median survival of 10.1
months (95% CI 0.9–19.3) with a probability of survival
at 1, 2 and 3 years of 32%, 16% and 0%. The effect of
baseline predictors and the treatment on survival of the
patients was assessed using a uni- and multivariate analy-
sis. Thus, a low Child-Pugh-score, a low score in the
Okuda- and CLIP-classification or a low AFP-level at study
entry were associated with better survival (Table 3). In
contrast, treatment with therapy modalities other than
thymostimulin before or after study entry or signs of an
invasive HCC phenotype such as vascular invasion or ext-
rahepatic metastases had no significant impact on sur-
vival. The only variables independently related to survival
in the Cox's regression model were Okuda stage (Figure 2)
and presence of liver cirrhosis at baseline (negative corre-
lation, p < 0.01) as well as the response to treatment (pos-
itive correlation, p < 0.05; Figure 3).
Response and progression-free survival
39 (88.6%) out of 44 patients were analysable for treat-
ment response. Response rates and the associated median
survival are depicted in Table 4. Two patients achieved a
complete response and were alive at the time of analysis
(survival time 45.3 and 56.8 months, respectively). In the
first patient, the tumor became secondarily accessible to
local ablation after 10 months of treatment with thymos-
timulin. He received concomitant therapy with 2 sessions
of RFTA as stipulated in the protocol. 5 months later thy-
mostimulin was stopped and the patient remained free of
tumor until the time of analysis (treatment response 28
months). The second patient achieved a complete
response without concomitant therapy after 8 months of
treatment with thymostimulin. 5 months later, the study
medication was stopped and the patient remained free of
tumor for 11 months until tumor recurrence necessitating
further treatment outside of the study. Another 8 patients
in the study survived longer than 2 years. Of these, two
showed a partial response to thymostimulin, in one ren-
dering the tumor secondarily accessible to RFTA (survival
time 24.8 and 55.4 months, respectively). Further 6
patients achieved stable disease with the study medication
(survival time 24.4 to 37.1 months). All patients died of
tumor progress except for one, who died during an
attempted rescue therapy by hepatic resection after tumor
progress.
The median progression-free survival was 6.4 months
(95% CI 0.8–12; Figure 4) and was dependent on the
score in the Okuda- (p < 0.001) and CLIP-classification (p
< 0.01), the AFP-level (p < 0.001) and the treatment with
other therapy modalities than thymostimulin before or
after study entry (p < 0.01).
Toxicity
None of the patients suffered from severe adverse events
during therapy. Ten of the patients (23%) reported local
erythema, itching or pain at the injection site (grade I on
ECOG common toxicity criteria). No patient had to
reduce or stop the study medication or had to be admitted
to the hospital due to side effects.
Discussion
While TACE has become the palliative treatment of choice
for HCC in patients with preserved liver function and
tumors limited to the liver parenchyma [13,14], there is
no standard treatment for HCC exceeding these criteria or
failing conventional therapy. In our phase II study, we
used the immunomodulatory compound thymostimulin,
Estimate of overall survival Figure 1
Estimate of overall survival. Kaplan-Meier graph showing 
probability of survival over time in percentage of patients 
treated (-- survival function, + censored).
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Table 2: Reasons for termination of treatment and cause of 
death
Termination of 
treatment (n = 44)
Death within 6 weeks of study entry§ 5
Tumor progression 29
Hepatic failure with stable disease§ 5
Other* 3
CR (one patient with concomitant RFTA) 2
* pneumonia after femur fracture, ventricular fibrillation and 
haemorrhage during surgical resection
§ cause of death hepatic failure without proven tumor progressBMC Cancer 2008, 8:72 http://www.biomedcentral.com/1471-2407/8/72
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a standardized thymic peptide fraction, to treat patients
with advanced HCC not suitable or refractory to therapy
options such as resection, RFTA or TACE. A similar phase
II study was published in 1996 on 46 patients with
advanced HCC not eligible for surgery, reporting an over-
all tumor response rate of 24% and a tumor control rate
of 63% [6]. 13% of patients obtained a complete response
with a median duration of 19 months and a median sur-
vival of 27 months compared with 4 months in the 37%
of patients with progressive disease. Despite the promis-
ing results however, the publication missed out criteria to
distinguish between responders and non-responders to
thymostimulin and thus to select patients who would
likely benefit from treatment.
Similar results were obtained in our study using thymos-
timulin with a one- and two-year-survival better than
anticipated by Okuda [15] or the Clip Study Group [16],
bearing in mind the selection of our patients not suitable
or refractory to conventional therapy (Table 5). Recently,
the Barcelona Clinic Liver Cancer (BCLC) staging classifi-
cation was established proposing treatment options and
survival probabilities for early (A), intermediate (B),
advanced (C) and terminal (D) stage HCC [17]. Data for
stage C and D of the disease were in part based on an anal-
ysis of the combined control arms of a chemoembolisa-
tion and a tamoxifen trial, thus providing the natural
history of untreated HCC [18]. While patients in group C
still had a 1-, 2- and 3-year survival of 29%, 16% and 8%,
respectively, patients in group D had a life expectancy of
less than 6 months. Comparisons with our data are com-
plicated by the fact that our study population included
patients with both, BCLC stage C and D of the disease.
However, an effect of thymostimulin over best supportive
care will only be proven in a randomized controlled trial,
highlighted recently by the failure of other alternative
treatment options such as doxorubicin, tamoxifen or
octreotide in meta-analyses or phase III studies [19-21].
The only possible new therapy for advanced HCC with a
survival benefit over best supportive care in a large con-
trolled trial is the protein kinase inhibitor sorafenib, pre-
sented to date only in a meeting abstract [4,22]. Its effect,
however, has only been proven for selected patients with
well-preserved liver function (not more than 5–6 Child
Pugh points) and at the expense of common side-effects
in up to 78% of cases [23,24].
Table 3: Variables associated with overall survival in the univariate analysis
Variables No. of patients Median survival (months ± SD) p-value
Overall 44 (100%) 11.5 ± 1.8
No cirrhosis/Child A 30 (68%) 13.7 ± 1.7
Child B 9 (21%) 6.3 ± 2.8 p = 0.01
Child C 5 (11%) 0.4 ± 0.1
Okuda stage I 13 (29%) 15.7 ± 6.4
Okuda stage II 28 (64%) 10.4 ± 1.7 p < 0.001
Okuda stage III 3 (7%) 0.4 ± 0.0
CLIP 0 2 37.1*
CLIP 1 10 13.7 ± 2.7
CLIP 2 15 13.6 ± 2.7 p < 0.001
CLIP 3 10 8.1 ± 1.6
CLIP 4–6 7 0.5 ± 0.1
AFP < 400 ng/ml 29 (66%) 16.2 ± 3.5 p < 0.001
AFP > 400 ng/ml 15 (34%) 6.3 ± 2.6
thymostimulin only 19 (43%) 10.1 ± 4.7 p = 0.1
additional therapy modalities 25 (57%) 13.7 ± 2.1
no vascular invasion 30 (68%) 11.5 ± 2.2 p = 0.3
with vascular invasion 14 (32%) 10.8 ± 2.8
no extrahepatic metastases 35 (79%) 13 ± 1.7 p = 0.1
with extrahepatic metastases 9 (21%) 8 ± 7.5
* SD not applicable due to low patient numberBMC Cancer 2008, 8:72 http://www.biomedcentral.com/1471-2407/8/72
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Interestingly, the Barcelona data showed cancer-related
symptoms and an invasive HCC phenotype with vascular
invasion or extrahepatic spread to be the best predictors of
outcome for intermediate and advanced tumors [18]. In
contrast, outcome in our study rather depended on liver
function and intrahepatic tumor growth (presence of liver
cirrhosis and Okuda stage) in addition to response to thy-
mostimulin, while an invasive or metastatic HCC pheno-
type had no influence in the multivariate analysis. It may
thus be speculated, that the immunmodulatory effect of
thymostimulin requires a functioning immune system.
All postulated antineoplastic pathways of thymostimulin
– stimulation of T lymphocytes to release interleukin-2
and interferons or activation of Kupffer and Natural Killer
cells with release of tumor necrosis factor-α [9,10] – are
impeded by a deteriorating liver function [25-27]. Indeed,
HCC growth itself has been linked to a depressed immune
function in patients with liver cirrhosis [28]. Thus, the
therapeutic impact of thymostimulin appears also to
Table 4: Tumor response and associated median survival (n = 39)
No. of patients Median survival (range) 95% CI
Complete response (CR) 2 (5%) > 51 months*
with concomitant treatment (RFTA) 1 (> 51 months*)
without concomitant treatment 1 (> 51 months*)
Partial response (PR) 5 (13%) 18 months 14–22
with concomitant treatment (TACE/RFTA) 2 (range 15.7–55.4)
without concomitant treatment 3 (range 3.9–24.8)
Stable disease (SD) 24 (61%) 14 months 11–17
Progressive disease (PD) 8 (21%) 4 months 0 – 8
Objective response (CR+PR) 7 (18%) 25 months 20–29
Tumor control rate (CR+PR+SD) 31 (79%) 16 months 11–20
* patients alive at time of analysis
Estimate of overall survival according to Okuda stage Figure 2
Estimate of overall survival according to Okuda 
stage. Kaplan-Meier graph showing probability of survival 
over time in percentage of patients treated and according to 
the Okuda stage of the hepatocellular carcinoma (-- survival 
function, + censored).
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Estimate of overall survival according to response to 
study treatment. Kaplan-Meier graph showing probability 
of survival over time in percentage of patients treated and 
according to the response to the study treatment with thy-
mostimulin (-- survival function, + censored).
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depend on a preserved liver function and a limited intra-
hepatic tumor size.
An effect of the treatment modalities prior or in addition
to thymostimulin has to be assumed in our study. Even
though the response to thymostimulin only, not treat-
ment with other modalities, was selected as a prognostic
factor in the multivariate analysis of overall survival, pro-
gression of the tumor was dependent on a multimodal
treatment. Obviously, thymostimulin is solely a palliative
treatment of HCC, although with a reasonable tumor
response rate (18%) and very good tumor growth control
(79%) in the present series compared with conventional
chemotherapy [14]. Since virtually no side-effects were
evident in this and the previous phase II study [6], it might
well be a suitable immunomodulatory component of a
multimodal antineoplastic therapy [29-31].
Conclusion
In conclusion, this phase II study confirms the previous
report on the potential efficacy and excellent safety profile
of thymostimulin in the treatment of HCC. As palliative
treatment, a controlled trial is required to unequivocally
demonstrate the superiority of thymostimulin over best
supportive care. Selection of the target population appears
to be necessary regarding liver function and intrahepatic
tumor growth, while an invasive or metastatic HCC phe-
notype has no impact on tumor response. Thus, thymos-
timulin might be a suitable and well-tolerated component
of a multimodal therapy concept for advanced HCC, in
particular in combination with local ablative strategies.
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